Brian Madajewski

Dr. Brian Madajewski

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
OOOlugbenga Okusanya
Olugbenga Okusanya
DHDavid Holt
David Holt
DHDaniel Heitjan
Daniel Heitjan
CDCharuhas Deshpande
Charuhas Deshpande
OVOllin Venegas
Ollin Venegas
SSSunil Singhal
Sunil Singhal

8 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FCFeng Chen
Feng Chen
KMKai Ma
Kai Ma
BMBrian Madajewski
Brian Madajewski
LZLi Zhuang
Li Zhuang
LZLi Zhang
Li Zhang
MBMichelle S. Bradbury
Michelle S. Bradbury
Controlling the biodistribution of nanoparticles upon intravenous injection is the key to achieving target specificity. One of the impediments in nanoparticle-based tumor targeting is the inability to limit the trafficking of nanoparticles to liver and other organs leading to smaller accumulated amounts in tumor tissues, particularly via passive targeting. Here we overcome both these challenges by designing nanoparticles that combine the specificity of antibodies with favorable particle biodistribution profiles, while not exceeding the threshold for renal filtration as a combined vehicle. To that end, ultrasmall silica nanoparticles are functionalized with anti-human epidermal growth factor receptor 2 (HER2) single-chain variable fragments to exhibit high tumor-targeting efficiency and efficient renal clearance. This ultrasmall targeted nanotheranostics/nanotherapeutic platform has broad utility, both for imaging a variety of tumor tissues by suitably adopting the targeting fragment and as a potentially useful drug delivery vehicle.

14 October 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BMBrian Madajewski
Brian Madajewski
BJBrendan F. Judy
Brendan F. Judy
AMAnas Mouchli
Anas Mouchli
VKVeena Kapoor
Veena Kapoor
DHDavid Holt
David Holt
SSSunil Singhal
Sunil Singhal
Purpose: Surgical resection remains the most effective therapy for solid tumors worldwide. The most important prognostic indicator for cure following cancer surgery is a complete resection with no residual disease. However, intraoperative detection of retained cancer cells after surgery is challenging, and residual disease continues to be the most common cause of local failure. We hypothesized that visual enhancement of tumors using near-infrared imaging could potentially identify tumor deposits in the wound after resection. Experimental Design: A small animal model of surgery and retained disease was developed. Residual tumor deposits in the wound were targeted using an U.S. Food and Drug Administration–approved imaging agent, indocyanine green, by the enhanced permeability and retention effect. A novel handheld spectrometer was used to optically visualize retained disease after surgery. Results: We found residual disease using near-infrared imaging during surgery that was not visible to the naked eye or micro-CT. Furthermore, examination of tumor nodules was remarkably precise in delineating margins from normal surrounding tissues. This approach was most successful for tumors with increased neovasculature. Conclusions: The results suggest that near-infrared examination of the surgical wound after curative resection can potentially enable the surgeon to locate residual disease. The data in this study is the basis of an ongoing Phase I/II clinical trial in patients who undergo resection for lung and breast cancer. Clin Cancer Res; 18(20); 5741–51. ©2012 AACR.

15 June 2015
Verified
Journal Article
Closed access
JJJack X Jiang
Jack X Jiang
JKJane J Keating
Jane J Keating
EJElizabeth M De Jesus
Elizabeth M De Jesus
RJRyan P Judy
Ryan P Judy
BMBrian Madajewski
Brian Madajewski
SSSunil Singhal
Sunil Singhal

6 September 2017 in Chemistry of Materials
Verified
Journal Article
Closed access
FCFeng Chen
Feng Chen
KMKai Ma
Kai Ma
LZLi Zhang
Li Zhang
BMBrian Madajewski
Brian Madajewski
PZPat Zanzonico
Pat Zanzonico
MBMichelle S. Bradbury
Michelle S. Bradbury

1 July 2015 in Journal of Biomedical Optics
Verified
Journal Article
Closed access
PDF file
DHDavid Holt
David Holt
APAshwin B. Parthasarathy
Ashwin B. Parthasarathy
OOOlugbenga T. Okusanya
Olugbenga T. Okusanya
JKJane Keating
Jane Keating
OVOllin Venegas
Ollin Venegas
SSSunil Singhal
Sunil Singhal
Surgery is the most effective method to cure patients with solid tumors, and 50% of all cancer patients undergo resection. Local recurrences are due to tumor cells remaining in the wound, thus we explore near-infrared (NIR) fluorescence spectroscopy and imaging to identify residual cancer cells after surgery. Fifteen canines and two human patients with spontaneously occurring sarcomas underwent intraoperative imaging. During the operation, the wounds were interrogated with NIR fluorescence imaging and spectroscopy. NIR monitoring identified the presence or absence of residual tumor cells after surgery in 14/15 canines with a mean fluorescence signal-to-background ratio (SBR) of ∼16. Ten animals showed no residual tumor cells in the wound bed (mean SBR<2, P<0.001). None had a local recurrence at <1-year follow-up. In five animals, the mean SBR of the wound was <15, and histopathology confirmed tumor cells in the postsurgical wound in four/five canines. In the human pilot study, neither patient had residual tumor cells in the wound bed, and both remain disease free at <1.5-year follow up. Intraoperative NIR fluorescence imaging and spectroscopy identifies residual tumor cells in surgical wounds. These observations suggest that NIR imaging techniques may improve tumor resection during cancer operations.